This clinical-stage biotech advances oncology therapies with a pipeline of novel small molecule inhibitors for hard-to-treat ...
That morning, Belite announced that its leading drug candidate, tinlarebant, met its primary endpoint in a phase 3 trial. The medicine was being tested to determine its efficacy in treating ...
Zacks Investment Research on MSN
Cabaletta Bio (CABA) upgraded to buy: Here's what you should know
Investors might want to bet on Cabaletta Bio, Inc. (CABA), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
Shares of Nuvation Bio (NYSE: NUVB) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday. The big jump came after two positive developments for the cancer-focused drugmaker. Which news ...
Asianet Newsable on MSN
Gossamer Bio stock plummeted 82% today — what’s behind the crash?
Gossamer Bio’s seralutinib did not achieve the predefined statistical bar for its main goal in the phase 3 PROSERA trial.
ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (PASG) (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results